{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:05:24Z","timestamp":1788185124231,"version":"build-2803163510"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Selectively inducing apoptosis of cancer cells is an effective therapeutic strategy, but the success of existing chemotherapeutics is compromised by emergent tumor cell resistance and systemic off-target effects. Therefore, the discovery of new pro-apoptotic compounds with minimal systemic side effects remains an urgent need. 14-3-3 proteins are molecular scaffolds that serve as important regulators of cell survival. We previously demonstrated that 14-3-3\u03b6 can sequester BAD, a pro-apoptotic member of the BCL-2 protein family, in the cytoplasm to inhibit the induction of apoptosis. Despite 14-3-3\u03b6 being a critical regulator of cell survival, the identification of molecules that potently disrupt 14-3-3\u03b6 actions has yet to materialize as a chemotherapeutic approach. Herein, we established a BRET-based, high-throughput drug screening approach (Z\u2019-score = 0.52) to identify molecules that disrupt the binding of 14-3-3\u03b6 to a BAD-derived fragment containing serine residues critical for their interactions. A drug library containing 1971 compounds was used for screening, and the capacity of identified hits to induce cell death was examined in NIH-3T3 fibroblasts and colorectal cancer cell lines, HT-29 and Caco-2. These results were mechanistically supported by both in silico structural analysis that suggest the possible mode of binding and direct biophysical measurements that demonstrate concentration-dependent target engagement. Terfenadine, penfluridol, and lomitapide have potential to either be repurposed as chemotherapeutics, or more likely, used as starting points for novel lead development. The described assay cascade demonstrates the feasibility of both expanding on these compounds and identifying novel disruptors of 14-3-3\u03b6 to develop pro-apoptotic agents to treat pathogenic aberrant cell growth.<\/jats:p>","DOI":"10.1038\/s41419-025-08150-6","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:17:49Z","timestamp":1762787869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A high-throughput screening approach to discover potential colorectal cancer chemotherapeutics: repurposing drugs to identify novel disruptors of 14-3-3 proteins"],"prefix":"10.1038","volume":"16","author":[{"given":"Siyi","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Meister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samra","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azam","family":"Mohammadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2721-5920","authenticated-orcid":false,"given":"Luis","family":"Delgadillo Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy A.","family":"Rutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4780-4968","authenticated-orcid":false,"given":"John F.","family":"Trant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3850-3757","authenticated-orcid":false,"given":"Gareth E.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"8150_CR1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cbin.11137","volume":"43","author":"MS D\u2019Arcy","year":"2019","unstructured":"D\u2019Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019;43:582\u201392.","journal-title":"Cell Biol Int"},{"key":"8150_CR2","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/cdd.2008.91","volume":"15","author":"K Labbe","year":"2008","unstructured":"Labbe K, Saleh M. Cell death in the host response to infection. Cell Death Differ. 2008;15:1339\u201349.","journal-title":"Cell Death Differ"},{"key":"8150_CR3","doi-asserted-by":"crossref","unstructured":"Pfeffer CM, Singh ATK. Apoptosis: a target for anticancer therapy. Int J Mol Sci. 2018;19:448.","DOI":"10.3390\/ijms19020448"},{"key":"8150_CR4","doi-asserted-by":"publisher","first-page":"24957","DOI":"10.1073\/pnas.2015372117","volume":"117","author":"CT Mayer","year":"2020","unstructured":"Mayer CT, Nieke JP, Gazumyan A, Cipolla M, Wang Q, Oliveira TY, et al. An apoptosis-dependent checkpoint for autoimmunity in memory B and plasma cells. Proc Natl Acad Sci USA. 2020;117:24957\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8150_CR5","unstructured":"Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society SCatPHAoC. Canadian Cancer Statistics: a 2024 special report on the economic impact of cancer in Canada. 2024."},{"key":"8150_CR6","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"8150_CR7","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2147\/CIA.S109285","volume":"11","author":"K Simon","year":"2016","unstructured":"Simon K. Colorectal cancer development and advances in screening. Clin Inter Aging. 2016;11:967\u201376.","journal-title":"Clin Inter Aging"},{"key":"8150_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1758834015614530","volume":"8","author":"WA Hammond","year":"2016","unstructured":"Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:57\u201384.","journal-title":"Ther Adv Med Oncol"},{"key":"8150_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Med. 2013;19:202\u20138.","journal-title":"Nature Med"},{"key":"8150_CR10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00125-012-2820-x","volume":"56","author":"GE Lim","year":"2013","unstructured":"Lim GE, Piske M, Johnson JD. 14-3-3 proteins are essential signalling hubs for beta cell survival. Diabetologia. 2013;56:825\u201337.","journal-title":"Diabetologia"},{"key":"8150_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S1097-2765(05)00012-2","volume":"6","author":"SR Datta","year":"2000","unstructured":"Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB, et al. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell. 2000;6:41\u201351.","journal-title":"Mol Cell"},{"key":"8150_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2018","unstructured":"Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25:65\u201380.","journal-title":"Cell Death Differ"},{"key":"8150_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0092-8674(00)81382-3","volume":"87","author":"J Zha","year":"1996","unstructured":"Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 1996;87:619\u201328.","journal-title":"Cell"},{"key":"8150_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0092-8674(95)90411-5","volume":"80","author":"E Yang","year":"1995","unstructured":"Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 1995;80:285\u201391.","journal-title":"Cell"},{"key":"8150_CR15","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrc1230","volume":"3","author":"H Hermeking","year":"2003","unstructured":"Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer. 2003;3:931\u201343.","journal-title":"Nat Rev Cancer"},{"key":"8150_CR16","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1517\/14728222.2010.531011","volume":"14","author":"CL Neal","year":"2010","unstructured":"Neal CL, Yu D. 14-3-3\u03b6 as a prognostic marker and therapeutic target for cancer. Expert Opin Ther Targets. 2010;14:1343\u201354.","journal-title":"Expert Opin Ther Targets"},{"key":"8150_CR17","doi-asserted-by":"publisher","first-page":"22379","DOI":"10.1074\/jbc.M109.022418","volume":"284","author":"SA Maxwell","year":"2009","unstructured":"Maxwell SA, Li Z, Jaya D, Ballard S, Ferrell J, Fu H. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen. J Biol Chem. 2009;284:22379\u201389.","journal-title":"J Biol Chem"},{"key":"8150_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/carcin\/bgy008","volume":"39","author":"J Ding","year":"2018","unstructured":"Ding J, Zhu YT, Yang L, Tang J, Wang YY, Chen Y, et al. 14-3-3zeta is involved in the anticancer effect of metformin in colorectal carcinoma. Carcinogenesis. 2018;39:493\u2013502.","journal-title":"Carcinogenesis"},{"key":"8150_CR19","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323:844\u201353.","journal-title":"JAMA"},{"key":"8150_CR20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/d41573-021-00190-9","volume":"21","author":"DG Brown","year":"2022","unstructured":"Brown DG, Wobst HJ, Kapoor A, Kenna LA, Southall N. Clinical development times for innovative drugs. Nat Rev Drug Discov. 2022;21:793\u20134.","journal-title":"Nat Rev Drug Discov"},{"key":"8150_CR21","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/cts.12577","volume":"11","author":"T Takebe","year":"2018","unstructured":"Takebe T, Imai R, Ono S. The current status of drug discovery and development as originated in United States Academia: the influence of industrial and academic collaboration on drug discovery and development. Clin Transl Sci. 2018;11:597\u2013606.","journal-title":"Clin Transl Sci"},{"key":"8150_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd5524","volume":"13","author":"CG Begley","year":"2021","unstructured":"Begley CG, Ashton M, Baell J, Bettess M, Brown MP, Carter B, et al. Drug repurposing: misconceptions, challenges, and opportunities for academic researchers. Sci Transl Med. 2021;13:eabd5524.","journal-title":"Sci Transl Med"},{"key":"8150_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41\u201358.","journal-title":"Nat Rev Drug Discov"},{"key":"8150_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44264-7","volume":"13","author":"MC De Rosa","year":"2023","unstructured":"De Rosa MC, Purohit R, Garcia-Sosa AT. Drug repurposing: a nexus of innovation, science, and potential. Sci Rep. 2023;13:17887.","journal-title":"Sci Rep"},{"key":"8150_CR25","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/med.21627","volume":"40","author":"CH Schein","year":"2020","unstructured":"Schein CH. Repurposing approved drugs on the pathway to novel therapies. Med Res Rev. 2020;40:586\u2013605.","journal-title":"Med Res Rev"},{"key":"8150_CR26","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1016\/j.bmc.2012.04.062","volume":"20","author":"BC Duffy","year":"2012","unstructured":"Duffy BC, Zhu L, Decornez H, Kitchen DB. Early phase drug discovery: cheminformatics and computational techniques in identifying lead series. Bioorg Med Chem. 2012;20:5324\u201342.","journal-title":"Bioorg Med Chem"},{"key":"8150_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1089\/adt.2013.507","volume":"11","author":"Y Du","year":"2013","unstructured":"Du Y, Fu RW, Lou B, Zhao J, Qui M, Khuri FR, et al. A time-resolved fluorescence resonance energy transfer assay for high-throughput screening of 14-3-3 protein-protein interaction inhibitors. Assay Drug Dev Technol. 2013;11:367\u201381.","journal-title":"Assay Drug Dev Technol"},{"key":"8150_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0165-6147(02)02062-X","volume":"23","author":"N Boute","year":"2002","unstructured":"Boute N, Jockers R, Issad T. The use of resonance energy transfer in high-throughput screening: BRET versus FRET. Trends Pharm Sci. 2002;23:351\u20134.","journal-title":"Trends Pharm Sci"},{"key":"8150_CR29","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1242\/jcs.00990","volume":"117","author":"MJ van Hemert","year":"2004","unstructured":"van Hemert MJ, Niemantsverdriet M, Schmidt T, Backendorf C, Spaink HP. Isoform-specific differences in rapid nucleocytoplasmic shuttling cause distinct subcellular distributions of 14-3-3 sigma and 14-3-3 zeta. J Cell Sci. 2004;117:1411\u201320.","journal-title":"J Cell Sci"},{"key":"8150_CR30","doi-asserted-by":"publisher","first-page":"R883","DOI":"10.1016\/S0960-9822(00)00843-5","volume":"10","author":"K Virdee","year":"2000","unstructured":"Virdee K, Parone PA, Tolkovsky AM. Phosphorylation of the pro-apoptotic protein BAD on serine 155, a novel site, contributes to cell survival. Curr Biol. 2000;10:R883.","journal-title":"Curr Biol"},{"key":"8150_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1738","volume":"3","author":"J Goedhart","year":"2012","unstructured":"Goedhart J, von Stetten D, Noirclerc-Savoye M, Lelimousin M, Joosen L, Hink MA, et al. Structure-guided evolution of cyan fluorescent proteins towards a quantum yield of 93%. Nat Commun. 2012;3:751.","journal-title":"Nat Commun"},{"key":"8150_CR32","doi-asserted-by":"publisher","first-page":"29188","DOI":"10.1074\/jbc.M102815200","volume":"276","author":"O Griesbeck","year":"2001","unstructured":"Griesbeck O, Baird GS, Campbell RE, Zacharias DA, Tsien RY. Reducing the environmental sensitivity of yellow fluorescent protein. Mechanism Appl J Biol Chem. 2001;276:29188\u201394.","journal-title":"Mechanism Appl J Biol Chem"},{"key":"8150_CR33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-2818.2006.01706.x","volume":"224","author":"S Bolte","year":"2006","unstructured":"Bolte S, Cordelieres FP. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc. 2006;224:213\u201332.","journal-title":"J Microsc"},{"key":"8150_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"JH Zhang","year":"1999","unstructured":"Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999;4:67\u201373.","journal-title":"J Biomol Screen"},{"key":"8150_CR35","doi-asserted-by":"crossref","unstructured":"Brown NE, Blumer JB, Hepler JR. Bioluminescence Resonance Energy Transfer to Detect Protein-Protein Interactions in Live Cells. In: Protein-Protein Interactions: Methods and Applications. Methods in Molecular Biology. 2015;1278:457\u201365.","DOI":"10.1007\/978-1-4939-2425-7_30"},{"key":"8150_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.molcel.2005.08.032","volume":"20","author":"N Macdonald","year":"2005","unstructured":"Macdonald N, Welburn JP, Noble ME, Nguyen A, Yaffe MB, Clynes D, et al. Molecular basis for the recognition of phosphorylated and phosphoacetylated histone H3 by 14-3-3. Mol Cell. 2005;20:199\u2013211.","journal-title":"Mol Cell"},{"key":"8150_CR37","doi-asserted-by":"publisher","first-page":"13362","DOI":"10.1073\/pnas.0802252105","volume":"105","author":"B Barstow","year":"2008","unstructured":"Barstow B, Ando N, Kim CU, Gruner SM. Alteration of citrine structure by hydrostatic pressure explains the accompanying spectral shift. Proc Natl Acad Sci USA. 2008;105:13362\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8150_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41929-022-00895-z","volume":"6","author":"A Schenkmayerova","year":"2023","unstructured":"Schenkmayerova A, Toul M, Pluskal D, Baatallah R, Gagnot G, Pinto GP, et al. Catalytic mechanism for Renilla-type luciferases. Nature Catal. 2023;6:23\u201338.","journal-title":"Nature Catal"},{"key":"8150_CR39","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1021\/acs.jctc.5b00436","volume":"11","author":"Y Miao","year":"2015","unstructured":"Miao Y, Feher VA, McCammon JA. Gaussian accelerated molecular dynamics: unconstrained enhanced sampling and free energy calculation. J Chem Theory Comput. 2015;11:3584\u201395.","journal-title":"J Chem Theory Comput"},{"key":"8150_CR40","unstructured":"Case DA, Belfon K, Ben-Shalom IY, Brozell SR, Cerutti DS, Cheatham III TE, et al. AMBER 2020. San Francisco: University of California; 2020."},{"key":"8150_CR41","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1021\/jz501780a","volume":"5","author":"S Izadi","year":"2014","unstructured":"Izadi S, Anandakrishnan R, Onufriev AV. Building water models: a different approach. J Phys Chem Lett. 2014;5:3863\u201371.","journal-title":"J Phys Chem Lett"},{"key":"8150_CR42","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","volume":"23","author":"J-P Ryckaert","year":"1977","unstructured":"Ryckaert J-P, Ciccotti G, Berendsen HJC. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys. 1977;23:327\u201341.","journal-title":"J Comput Phys"},{"key":"8150_CR43","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1021\/ct400341p","volume":"9","author":"DR Roe","year":"2013","unstructured":"Roe DR, Cheatham TE. 3rd. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput. 2013;9:3084\u201395.","journal-title":"J Chem Theory Comput"},{"key":"8150_CR44","doi-asserted-by":"publisher","first-page":"13470","DOI":"10.1002\/anie.201806584","volume":"57","author":"SA Andrei","year":"2018","unstructured":"Andrei SA, de Vink P, Sijbesma E, Han L, Brunsveld L, Kato N, et al. Rationally designed semisynthetic natural product analogues for stabilization of 14-3-3 protein-protein interactions. Angewandte Chem. 2018;57:13470\u20134.","journal-title":"Angewandte Chem"},{"key":"8150_CR45","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1021\/acsmedchemlett.9b00541","volume":"11","author":"AM Hartman","year":"2020","unstructured":"Hartman AM, Elgaher WAM, Hertrich N, Andrei SA, Ottmann C, Hirsch AKH. Discovery of small-molecule stabilizers of 14-3-3 protein-protein interactions via dynamic combinatorial chemistry. ACS Med Chem Lett. 2020;11:1041\u20136.","journal-title":"ACS Med Chem Lett"},{"key":"8150_CR46","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1038\/s41388-018-0348-3","volume":"37","author":"KL Pennington","year":"2018","unstructured":"Pennington KL, Chan TY, Torres MP, Andersen JL. The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein-protein interactions. Oncogene. 2018;37:5587\u2013604.","journal-title":"Oncogene"},{"key":"8150_CR47","doi-asserted-by":"publisher","first-page":"12499","DOI":"10.1021\/bi991353h","volume":"38","author":"B Wang","year":"1999","unstructured":"Wang B, Yang H, Liu Y-C, Jelinek T, Zhang L, Ruoslahti E, et al. Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry. 1999;38:12499\u2013504.","journal-title":"Biochemistry"},{"key":"8150_CR48","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.cellsig.2010.04.004","volume":"22","author":"JM Woodcock","year":"2010","unstructured":"Woodcock JM, Ma Y, Coolen C, Pham D, Jones C, Lopez AF, et al. Sphingosine and FTY720 directly bind pro-survival 14-3-3 proteins to regulate their function. Cell Signal. 2010;22:1291\u20139.","journal-title":"Cell Signal"},{"key":"8150_CR49","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1002\/anie.201003257","volume":"49","author":"H Wu","year":"2010","unstructured":"Wu H, Ge J, Yao SQ. Microarray-assisted high-throughput identification of a cell-permeable small-molecule binder of 14-3-3 proteins. Angewandte Chem. 2010;49:6528\u201332.","journal-title":"Angewandte Chem"},{"key":"8150_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.202200151","volume":"7","author":"S He","year":"2023","unstructured":"He S, Lim GE. The application of high-throughput approaches in identifying novel therapeutic targets and agents to treat diabetes. Adv Biol. 2023;7:e2200151.","journal-title":"Adv Biol"},{"key":"8150_CR51","doi-asserted-by":"publisher","first-page":"pdb prot087379","DOI":"10.1101\/pdb.prot087379","volume":"2016","author":"M Feoktistova","year":"2016","unstructured":"Feoktistova M, Geserick P, Leverkus M. Crystal violet assay for determining viability of cultured cells. Cold Spring Harb Protoc. 2016;2016:pdb prot087379.","journal-title":"Cold Spring Harb Protoc"},{"key":"8150_CR52","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/j.identj.2023.08.009","volume":"73","author":"Z Brookes","year":"2023","unstructured":"Brookes Z, McGrath C, McCullough M. Antimicrobial mouthwashes: an overview of mechanisms-what do we still need to know?. Int Dent J. 2023;73:S64\u2013s8.","journal-title":"Int Dent J"},{"key":"8150_CR53","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1111\/jam.15739","volume":"133","author":"JY Maillard","year":"2022","unstructured":"Maillard JY. Impact of benzalkonium chloride, benzethonium chloride and chloroxylenol on bacterial antimicrobial resistance. J Appl Microbiol. 2022;133:3322\u201346.","journal-title":"J Appl Microbiol"},{"key":"8150_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-020-00181-5","volume":"7","author":"A Simon-Soro","year":"2021","unstructured":"Simon-Soro A, Kim D, Li Y, Liu Y, Ito T, Sims KR Jr, et al. Impact of the repurposed drug thonzonium bromide on host oral-gut microbiomes. NPJ Biofilms Microbiomes. 2021;7:7.","journal-title":"NPJ Biofilms Microbiomes"},{"key":"8150_CR55","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1021\/acschembio.7b00903","volume":"13","author":"JB Baell","year":"2018","unstructured":"Baell JB, Nissink JWM. Seven year itch: pan-assay interference compounds (PAINS) in 2017\u2014utility and limitations. ACS Chem Biol. 2018;13:36\u201344.","journal-title":"ACS Chem Biol"},{"key":"8150_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105463","volume":"165","author":"R Roskoski Jr","year":"2021","unstructured":"Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update. Pharmacol Res. 2021;165:105463.","journal-title":"Pharmacol Res"},{"key":"8150_CR57","doi-asserted-by":"publisher","first-page":"6867","DOI":"10.1016\/j.bmcl.2011.09.011","volume":"21","author":"V Corradi","year":"2011","unstructured":"Corradi V, Mancini M, Santucci MA, Carlomagno T, Sanfelice D, Mori M, et al. Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3sigma case. Bioorg Med Chem Lett. 2011;21:6867\u201371.","journal-title":"Bioorg Med Chem Lett"},{"key":"8150_CR58","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/14756366.2019.1574779","volume":"34","author":"L Iralde-Lorente","year":"2019","unstructured":"Iralde-Lorente L, Cau Y, Clementi L, Franci L, Tassone G, Valensin D, et al. Chemically stable inhibitors of 14-3-3 protein-protein interactions derived from BV02. J Enzym Inhib Med Chem. 2019;34:657\u201364.","journal-title":"J Enzym Inhib Med Chem"},{"key":"8150_CR59","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.1016\/j.bmcl.2010.08.019","volume":"20","author":"V Corradi","year":"2010","unstructured":"Corradi V, Mancini M, Manetti F, Petta S, Santucci MA, Botta M. Identification of the first non-peptidic small molecule inhibitor of the c-Abl\/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. Bioorg Med Chem Lett. 2010;20:6133\u20137.","journal-title":"Bioorg Med Chem Lett"},{"key":"8150_CR60","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1078\/0065-1281-00601","volume":"103","author":"CJ Van Noorden","year":"2001","unstructured":"Van Noorden CJ. The history of Z-VAD-FMK, a tool for understanding the significance of caspase inhibition. Acta Histochem. 2001;103:241\u201351.","journal-title":"Acta Histochem"},{"key":"8150_CR61","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/ijc.20371","volume":"112","author":"Y Andersson","year":"2004","unstructured":"Andersson Y, Juell S, Fodstad O. Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin. Int J Cancer. 2004;112:475\u201383.","journal-title":"Int J Cancer"},{"key":"8150_CR62","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1038\/leu.2017.132","volume":"31","author":"J Yu","year":"2017","unstructured":"Yu J, Chen L, Chen Y, Hasan MK, Ghia EM, Zhang L, et al. Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia. 2017;31:2608\u201314.","journal-title":"Leukemia"},{"key":"8150_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-13-53","volume":"13","author":"L Jiang","year":"2013","unstructured":"Jiang L, Luo M, Liu D, Chen B, Zhang W, Mai L, et al. BAD overexpression inhibits cell growth and induces apoptosis via mitochondrial-dependent pathway in non-small cell lung cancer. Cancer Cell Int. 2013;13:53.","journal-title":"Cancer Cell Int"},{"key":"8150_CR64","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3389\/fendo.2018.00512","volume":"9","author":"X Cao","year":"2018","unstructured":"Cao X, Wang X, Lu L, Li X, Di R, He X, et al. Expression and functional analysis of the BCL2-associated agonist of cell death (BAD) gene in the sheep ovary during the reproductive cycle. Front Endocrinol. 2018;9:512.","journal-title":"Front Endocrinol."},{"key":"8150_CR65","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/sj.cdd.4401097","volume":"9","author":"M Adachi","year":"2002","unstructured":"Adachi M, Imai K. The proapoptotic BH3-only protein BAD transduces cell death signals independently of its interaction with Bcl-2. Cell Death Differ. 2002;9:1240\u20137.","journal-title":"Cell Death Differ"},{"key":"8150_CR66","doi-asserted-by":"crossref","unstructured":"Obsilova V, Obsil T. Structural insights into the functional roles of 14-3-3 proteins. Front Mol Biosci. 2022;9:1016071.","DOI":"10.3389\/fmolb.2022.1016071"},{"key":"8150_CR67","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1124\/mol.60.6.1325","volume":"60","author":"SC Masters","year":"2001","unstructured":"Masters SC, Yang H, Datta SR, Greenberg ME, Fu H. 14-3-3 inhibits Bad-induced cell death through interaction with serine-136. Mol Pharm. 2001;60:1325\u201331.","journal-title":"Mol Pharm"},{"key":"8150_CR68","doi-asserted-by":"publisher","first-page":"17237","DOI":"10.1073\/pnas.0605779103","volume":"103","author":"X Yang","year":"2006","unstructured":"Yang X, Lee WH, Sobott F, Papagrigoriou E, Robinson CV, Grossmann JG, et al. Structural basis for protein-protein interactions in the 14-3-3 protein family. Proc Natl Acad Sci USA. 2006;103:17237\u201342.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8150_CR69","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835\u201344.","journal-title":"Nat Rev Drug Discov"},{"key":"8150_CR70","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1021\/jm049354h","volume":"48","author":"PL Toogood","year":"2005","unstructured":"Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6. J Med Chem. 2005;48:2388\u2013406.","journal-title":"J Med Chem"},{"key":"8150_CR71","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1021\/jm0507532","volume":"49","author":"AM Petros","year":"2006","unstructured":"Petros AM, Dinges J, Augeri DJ, Baumeister SA, Betebenner DA, Bures MG, et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem. 2006;49:656\u201363.","journal-title":"J Med Chem"},{"key":"8150_CR72","doi-asserted-by":"publisher","first-page":"834453","DOI":"10.3389\/fmolb.2022.834453","volume":"9","author":"LG Mureddu","year":"2022","unstructured":"Mureddu LG, Vuister GW. Fragment-based drug discovery by NMR. Where are the successes and where can it be improved?. Front Mol Biosci. 2022;9:834453.","journal-title":"Front Mol Biosci"},{"key":"8150_CR73","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/nrd3368","volume":"10","author":"R Macarron","year":"2011","unstructured":"Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, et al. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov. 2011;10:188\u201395.","journal-title":"Nat Rev Drug Discov"},{"key":"8150_CR74","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nbt1186","volume":"24","author":"N Malo","year":"2006","unstructured":"Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R. Statistical practice in high-throughput screening data analysis. Nat Biotechnol. 2006;24:167\u201375.","journal-title":"Nat Biotechnol"},{"key":"8150_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/srep25631","volume":"6","author":"Z Shao","year":"2016","unstructured":"Shao Z, Cai Y, Xu L, Yao X, Shi J, Zhang F, et al. Loss of the 14-3-3\u03c3 is essential for LASP1-mediated colorectal cancer progression via activating PI3K\/AKT signaling pathway. Scientific Rep. 2016;6:25631.","journal-title":"Scientific Rep"},{"key":"8150_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1856-y","volume":"15","author":"GM Young","year":"2015","unstructured":"Young GM, Radhakrishnan VM, Centuori SM, Gomes CJ, Martinez JD. Comparative analysis of 14-3-3 isoform expression and epigenetic alterations in colorectal cancer. BMC Cancer. 2015;15:826.","journal-title":"BMC Cancer"},{"key":"8150_CR77","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0016-5085(89)80072-1","volume":"96","author":"IJ Hidalgo","year":"1989","unstructured":"Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology. 1989;96:736\u201349.","journal-title":"Gastroenterology"},{"key":"8150_CR78","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0922-3371(90)90133-H","volume":"31","author":"M Hekmati","year":"1990","unstructured":"Hekmati M, Polak-Charcon S, Ben-Shaul Y. A morphological study of a human adenocarcinoma cell line (HT29) differentiating in culture. Similarities to intestinal embryonic development. Cell Differ Dev. 1990;31:207\u201318.","journal-title":"Cell Differ Dev"},{"key":"8150_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-01898-9","volume":"21","author":"E Gheytanchi","year":"2021","unstructured":"Gheytanchi E, Naseri M, Karimi-Busheri F, Atyabi F, Mirsharif ES, Bozorgmehr M, et al. Morphological and molecular characteristics of spheroid formation in HT-29 and Caco-2 colorectal cancer cell lines. Cancer Cell Int. 2021;21:204.","journal-title":"Cancer Cell Int"},{"key":"8150_CR80","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/sj.bjp.0706919","volume":"149","author":"HL Zhu","year":"2006","unstructured":"Zhu HL, Tomoda T, Aishima M, Ito Y, Teramoto N. The actions of azelnidipine, a dihydropyridine-derivative Ca antagonist, on voltage-dependent Ba2+ currents in guinea-pig vascular smooth muscle. Br J Pharm. 2006;149:786\u201396.","journal-title":"Br J Pharm"},{"key":"8150_CR81","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","volume":"369","author":"D de Zeeuw","year":"2013","unstructured":"de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369:2492\u2013503.","journal-title":"N Engl J Med"},{"key":"8150_CR82","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/1535-7163.MCT-06-0516","volume":"6","author":"MS Yates","year":"2007","unstructured":"Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther. 2007;6:154\u201362.","journal-title":"Mol Cancer Ther"},{"key":"8150_CR83","doi-asserted-by":"publisher","first-page":"100433","DOI":"10.18632\/oncotarget.22247","volume":"8","author":"SJ Kang","year":"2017","unstructured":"Kang SJ, Lee YJ, Kang SG, Cho S, Yoon W, Lim JH, et al. Caspase-4 is essential for saikosaponin a-induced apoptosis acting upstream of caspase-2 and gamma-H2AX in colon cancer cells. Oncotarget. 2017;8:100433\u201348.","journal-title":"Oncotarget"},{"key":"8150_CR84","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.bmcl.2015.12.066","volume":"26","author":"D Valensin","year":"2016","unstructured":"Valensin D, Cau Y, Calandro P, Vignaroli G, Dello Iacono L, Chiariello M, et al. Molecular insights to the bioactive form of BV02, a reference inhibitor of 14-3-3sigma protein-protein interactions. Bioorg Med Chem Lett. 2016;26:894\u20138.","journal-title":"Bioorg Med Chem Lett"},{"key":"8150_CR85","doi-asserted-by":"crossref","unstructured":"Iralde-Lorente L, Botta M, Ottmann C. Small-molecule modulators of protein\u2013protein interactions: focus on 14-3-3 PPIs. In: Roy S, Fu H, editors. Protein\u2013protein interaction regulators. The Royal Society of Chemistry; 2020.","DOI":"10.1039\/9781788016544-00249"},{"key":"8150_CR86","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/cdd.2016.7","volume":"23","author":"S Nagata","year":"2016","unstructured":"Nagata S, Suzuki J, Segawa K, Fujii T. Exposure of phosphatidylserine on the cell surface. Cell Death Differ. 2016;23:952\u201361.","journal-title":"Cell Death Differ"},{"key":"8150_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/srep32447","volume":"6","author":"R Guo","year":"2016","unstructured":"Guo R, Lin B, Pan JF, Liong EC, Xu AM, Youdim M, et al. Inhibition of caspase-9 aggravates acute liver injury through suppression of cytoprotective autophagy. Scientific Rep. 2016;6:32447.","journal-title":"Scientific Rep"},{"key":"8150_CR88","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/cdd.2010.72","volume":"18","author":"YT Wu","year":"2011","unstructured":"Wu YT, Tan HL, Huang Q, Sun XJ, Zhu X, Shen HM. zVAD-induced necroptosis in L929 cells depends on autocrine production of TNFalpha mediated by the PKC-MAPKs-AP-1 pathway. Cell Death Differ. 2011;18:26\u201337.","journal-title":"Cell Death Differ"},{"key":"8150_CR89","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.semcdb.2012.05.004","volume":"23","author":"W Hong","year":"2012","unstructured":"Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012;23:785\u201393.","journal-title":"Semin Cell Dev Biol"},{"key":"8150_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.slasd.2024.100191","volume":"29","author":"B Andlovic","year":"2024","unstructured":"Andlovic B, Wolf A, Hiltmann M, Klebl BM, Eickhoff J, Ottmann C. Development of a live cell assay for real-time monitoring the interactions between the Hippo pathway components 14-3-3 and TAZ. SLAS Discov. 2024;29:100191.","journal-title":"SLAS Discov"},{"key":"8150_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.slasd.2024.100165","volume":"29","author":"HR Vickery","year":"2024","unstructured":"Vickery HR, Virta JM, Konstantinidou M, Arkin MR. Development of a NanoBRET assay for evaluation of 14-3-3sigma molecular glues. SLAS Discov. 2024;29:100165.","journal-title":"SLAS Discov"},{"key":"8150_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.562196","volume":"10","author":"M Varalda","year":"2020","unstructured":"Varalda M, Antona A, Bettio V, Roy K, Vachamaram A, Yellenki V, et al. Psychotropic drugs show anticancer activity by disrupting mitochondrial and lysosomal function. Front Oncol. 2020;10:562196.","journal-title":"Front Oncol"},{"key":"8150_CR93","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.canlet.2021.09.010","volume":"521","author":"Q Zuo","year":"2021","unstructured":"Zuo Q, Liao L, Yao Z-T, Liu Y-P, Wang D-K, Li S-J, et al. Targeting PP2A with lomitapide suppresses colorectal tumorigenesis through the activation of AMPK\/Beclin1-mediated autophagy. Cancer Lett. 2021;521:281\u201393.","journal-title":"Cancer Lett"},{"key":"8150_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05039-6","volume":"13","author":"B Lee","year":"2022","unstructured":"Lee B, Park SJ, Lee S, Lee J, Lee E, Yoo ES, et al. Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR. Cell Death Dis. 2022;13:603.","journal-title":"Cell Death Dis"},{"key":"8150_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1418266","volume":"15","author":"MK Baniya","year":"2024","unstructured":"Baniya MK, Kim EH, Chun KS. Terfenadine, a histamine H1 receptor antagonist, induces apoptosis by suppressing STAT3 signaling in human colorectal cancer HCT116 cells. Front Pharm. 2024;15:1418266.","journal-title":"Front Pharm"},{"key":"8150_CR96","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fphar.2020.00524","volume":"11","author":"S Hua","year":"2020","unstructured":"Hua S. Advances in oral drug delivery for regional targeting in the gastrointestinal tract\u2014influence of physiological, pathophysiological and pharmaceutical factors. Front Pharm. 2020;11:524.","journal-title":"Front Pharm"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08150-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08150-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08150-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:10:25Z","timestamp":1762884625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08150-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8150"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08150-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5242408\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"14 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SH, DM, and LD have nothing to disclose. GEL was a consultant for Diogenix and Ambagon Therapeutics and has received research funding from Inversago Pharma, a Novo Nordisk Company. GAR has received grant funding from, and is a consultant for, Sun Pharmaceuticals Inc. JFT is CEO of Binary Star Research Services, which has no interests in the subject of this work, holds no relevant IP, and neither received, nor provided, any funding associated with this work. BSRS had no input into the methods used, or the conclusions of this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experiments were done in accordance with the rules and regulations and guidelines of the Centre de Recherche du Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM) and the University of Windsor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}],"article-number":"825"}}